MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/adm.0000000000001337

Медицинская библиотека · Journal of addiction medicine · 2024

Naloxone Use During Pregnancy-Data From 26 US Jurisdictions, 2019-2020.

Board Amy, D'Angelo Denise V, Miele Kathryn, Asher Alice, Salvesen von Essen Beatriz, Denny Clark H, Terplan Mishka, Dunkley Janae, Kim Shin Y

СтатьяПоддержка исследования: вне правительства СШАПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

OBJECTIVES

We aimed to determine the prevalence of self-reported naloxone use during pregnancy among people in the United States with a recent live birth. A secondary objective was to characterize people at increased risk of overdose who did and did not use naloxone.

METHODS

We analyzed data from the Pregnancy Risk Assessment Monitoring System from 26 US jurisdictions that conducted an opioid supplement survey from 2019 to 2020. Respondents with increased risk of experiencing an opioid overdose were identified based on self-reported use of illicit amphetamines, heroin, cocaine, or receiving medication for opioid use disorder (MOUD) during pregnancy. Weighted prevalence estimates and 95% confidence intervals were calculated for reported naloxone use at any point during pregnancy among people with an increased risk of overdose.

RESULTS

Naloxone use during pregnancy was reported by <1% of the overall study population (unweighted N = 88/34,528). Prevalence of naloxone use was 5.0% (95% CI: 0.0-10.6) among respondents who reported illicit amphetamine use, 15.2% (1.8-28.6) among those who reported heroin use, and 17.6% (0.0-38.1) among those who reported cocaine use. Naloxone use was 14.5% (8.4-20.6) among those who reported taking MOUD. Among people with increased risk of overdose, no significant differences in naloxone use were observed by age, race/ethnicity, education level, residential metropolitan status, or insurance status.

CONCLUSIONS

Prevalence of naloxone use among people with an increased risk of overdose during pregnancy ranged from 5.0% to 17.6%. Access to naloxone, overdose prevention education, and treatment for substance use disorders may help reduce morbidity and mortality.

Для цитирования: Board Amy, D'Angelo Denise V, Miele Kathryn, Asher Alice, Salvesen von Essen Beatriz, Denny Clark H, Terplan Mishka, Dunkley Janae, Kim Shin Y. Naloxone Use During Pregnancy-Data From 26 US Jurisdictions, 2019-2020.. Journal of addiction medicine. 2024. DOI: 10.1097/adm.0000000000001337.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.